CA2720632A1 - Analogues b de l'halichondrine - Google Patents

Analogues b de l'halichondrine Download PDF

Info

Publication number
CA2720632A1
CA2720632A1 CA2720632A CA2720632A CA2720632A1 CA 2720632 A1 CA2720632 A1 CA 2720632A1 CA 2720632 A CA2720632 A CA 2720632A CA 2720632 A CA2720632 A CA 2720632A CA 2720632 A1 CA2720632 A1 CA 2720632A1
Authority
CA
Canada
Prior art keywords
theta
monohydrate
crystalline
crystal
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA2720632A
Other languages
English (en)
Other versions
CA2720632C (fr
Inventor
Yongbo Hu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eisai R&D Management Co Ltd
Original Assignee
Eisai R&D Management Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Management Co Ltd filed Critical Eisai R&D Management Co Ltd
Publication of CA2720632A1 publication Critical patent/CA2720632A1/fr
Application granted granted Critical
Publication of CA2720632C publication Critical patent/CA2720632C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/22—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Saccharide Compounds (AREA)

Abstract

Cette invention concerne les analogues B de l'halichondrine ayant une activité pharmaceutique, dans certains cas, leurs formes cristallines, et dans certains cas, les analogues B de l'halichondrine ayant une utilité supplémentaire à titre d'intermédiaires de synthèse.
CA2720632A 2008-04-04 2009-04-03 Analogues b de l'halichondrine Active CA2720632C (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US4264308P 2008-04-04 2008-04-04
US61/042,643 2008-04-04
US7111108P 2008-04-11 2008-04-11
US61/071,111 2008-04-11
PCT/US2009/039432 WO2009124237A1 (fr) 2008-04-04 2009-04-03 Analogues b de l'halichondrine

Publications (2)

Publication Number Publication Date
CA2720632A1 true CA2720632A1 (fr) 2009-10-08
CA2720632C CA2720632C (fr) 2016-12-20

Family

ID=40674339

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2720632A Active CA2720632C (fr) 2008-04-04 2009-04-03 Analogues b de l'halichondrine

Country Status (11)

Country Link
US (3) US8598373B2 (fr)
EP (1) EP2274309B1 (fr)
JP (2) JP6001857B2 (fr)
CN (2) CN105801599A (fr)
BR (1) BRPI0911269A2 (fr)
CA (1) CA2720632C (fr)
IL (1) IL208410A (fr)
MX (1) MX2010010902A (fr)
RU (1) RU2517167C2 (fr)
SG (1) SG189739A1 (fr)
WO (1) WO2009124237A1 (fr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU227912B1 (en) * 1998-06-17 2012-05-29 Eisai R & D Man Co Halichondrin analogs and methods of their use and preparation
PL2522663T3 (pl) 2004-06-03 2015-08-31 Eisai R&D Man Co Ltd Produkty pośrednie do otrzymywania halichondryny B
CN108948039B (zh) 2007-10-03 2021-12-31 卫材R&D管理有限公司 用于合成软海绵素b类似物的中间体和方法
CN105801599A (zh) * 2008-04-04 2016-07-27 卫材R&D管理有限公司 软海绵素b类似物
CN102803254B (zh) 2010-01-26 2016-09-14 卫材R&D管理有限公司 用于软海绵素b类似物合成的呋喃并[3,2-b]吡喃衍生物
WO2012147900A1 (fr) 2011-04-28 2012-11-01 Eisai R&D Management Co., Ltd. Procédé en microréacteurs pour synthèse d'analogue d'halichondrine b
CA2857385A1 (fr) 2011-11-30 2013-06-06 Alphora Research Inc. Procede de preparation de (3r)-2,4-di-groupe partant-3-methylbut-1-ene
US9174956B2 (en) 2011-12-16 2015-11-03 Alphora Research Inc. Process for preparation of 3-((2S,5S)-4-methylene-5-(3-oxopropyl)tetrahydrofuran-2-yl)propanol derivatives and intermediates useful thereof
JP6300030B2 (ja) * 2011-12-29 2018-03-28 サンド アクツィエンゲゼルシャフト ２−（（２ｓ，３ｓ，４ｒ，５ｒ）−５−（（ｓ）−３−アミノ−２−ヒドロキシプロプ−１−イル）−４−メトキシ−３−（フェニルスルホニルメチル）テトラヒドロフラン−２−イル）アセトアルデヒド誘導体およびこれらを調製するためのプロセス
US9278979B2 (en) 2012-03-30 2016-03-08 Alphora Research Inc. Synthetic process for preparation of macrocyclic C1-keto analogs of halichondrin B and intermediates useful therein
MX2015007185A (es) 2012-12-04 2017-09-05 Eisai R&D Man Co Ltd Uso de eribulina en el tratamiento de cancer de pecho.
US9850254B2 (en) 2013-07-03 2017-12-26 Sandoz Ag Synthetic process for preparation of macrocyclic C1-keto analogs of Halichondrin B and intermediates useful therein including intermediates containing-SO2-(p-tolyl) groups
CN105683198B (zh) 2013-11-04 2019-03-12 卫材R&D管理有限公司 软海绵素b的类似物合成中有用的大环化反应和中间体
HUE043088T2 (hu) 2013-12-06 2019-08-28 Eisai R&D Man Co Ltd Halikondrin B analógok szintézisében alkalmazható eljárások
TW201617326A (zh) 2014-03-06 2016-05-16 Ａｌｐｈｏｒａ研發股份有限公司 （ｓ）－１－（（２ｒ，３ｒ，４ｓ，５ｓ）－５－烯丙－３－甲氧－４－（對甲苯磺醯甲基）四氫呋喃－２－基）－３－氨基丙－２－醇之結晶衍生物
EP3160970A4 (fr) 2014-06-30 2017-12-27 President and Fellows of Harvard College Synthèse d'analogues d'halochondrines et leurs utilisations
WO2016176560A1 (fr) 2015-04-30 2016-11-03 President And Fellows Of Harvard College Couplage induit par chrome et application à la synthèse d'halichondrines
RU2020141025A (ru) * 2015-05-07 2020-12-28 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Реакции макроциклизации и промежуточные соединения и другие фрагменты, полезные в синтезе макролидов галихондринов
US10676481B2 (en) 2016-02-12 2020-06-09 Eisai R&D Management Co., Ltd. Intermediates in the synthesis of eribulin and related methods of synthesis
SG11201811671XA (en) 2016-06-30 2019-01-30 Eisai R&D Man Co Ltd Prins reaction and intermediates useful in the synthesis of halichondrin macrolides and analogs thereof
JP6978758B2 (ja) 2016-11-11 2021-12-08 プレジデント アンド フェローズ オブ ハーバード カレッジ パラジウム媒介ケトール化
US9938288B1 (en) 2017-04-05 2018-04-10 President And Fellows Of Harvard College Macrocyclic compound and uses thereof
KR102836514B1 (ko) 2017-04-05 2025-07-22 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 마크로시클릭 화합물 및 그의 용도
US11498892B2 (en) 2017-07-06 2022-11-15 President And Fellows Of Harvard College Fe/Cu-mediated ketone synthesis
HUE061306T2 (hu) 2017-07-06 2023-06-28 Harvard College Halikondrinok szintézise
ES2974243T3 (es) 2017-11-15 2024-06-26 Harvard College Compuestos macrocíclicos y usos de los mismos
KR20250057138A (ko) 2018-01-03 2025-04-28 에자이 알앤드디 매니지먼트 가부시키가이샤 할리콘드린 마크롤리드 및 그의 유사체의 합성에 유용한 프린스 반응 및 화합물
JP2021532102A (ja) * 2018-07-20 2021-11-25 ドクター レディズ ラボラトリーズ リミテッド エリブリンおよびその中間体の調製のための精製プロセス
US20210340156A1 (en) * 2018-10-09 2021-11-04 Dr. Reddy's Laboratories Limited Process for preparation of eribulin and intermediates thereof
US11447499B2 (en) 2019-06-14 2022-09-20 Rk Pharma Inc. Process for the preparation of eribulin mesylate intermediate
WO2020255164A1 (fr) 2019-06-21 2020-12-24 Council Of Scientific And Industrial Research Procédé chimio-enzymatique pour la préparation d'alcool homopropargylique
CN114380840B (zh) * 2022-01-27 2024-01-26 江苏慧聚药业股份有限公司 艾日布林的合成

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5338865A (en) 1992-03-12 1994-08-16 President And Fellows Of Harvard College Synthesis of halichondrin B and norhalichondrin B
US5436238A (en) 1992-03-12 1995-07-25 President And Fellows Of Harvard College Halichondrins and related compounds
GB9206244D0 (en) 1992-03-23 1992-05-06 Pharma Mar Sa Cytotoxic compound from a marine sponge
TW255880B (fr) 1992-09-09 1995-09-01 Hoechst Ag
US6194586B1 (en) 1996-09-06 2001-02-27 Eli Lilly And Company Selective sulphonation of the primary alcohol of a diol containing both primary and secondary alcohols
US6653341B1 (en) 1998-06-17 2003-11-25 Eisai Co., Ltd. Methods and compositions for use in treating cancer
US8097648B2 (en) 1998-06-17 2012-01-17 Eisai R&D Management Co., Ltd. Methods and compositions for use in treating cancer
HU227912B1 (en) * 1998-06-17 2012-05-29 Eisai R & D Man Co Halichondrin analogs and methods of their use and preparation
PL2522663T3 (pl) 2004-06-03 2015-08-31 Eisai R&D Man Co Ltd Produkty pośrednie do otrzymywania halichondryny B
EP1831697A4 (fr) * 2004-12-09 2011-01-26 Eisai R&D Man Co Ltd Criblage de l'isotype tubuline en therapie du cancer faisant appel aux analogues de l'halichondrine b
CN108948039B (zh) 2007-10-03 2021-12-31 卫材R&D管理有限公司 用于合成软海绵素b类似物的中间体和方法
US20090203771A1 (en) 2007-11-16 2009-08-13 Eisai R&D Management Co., Ltd. Novel intermediate for halichondrin b analog synthesis and novel desulfonylation reaction used for the intermediate
CN105801599A (zh) 2008-04-04 2016-07-27 卫材R&D管理有限公司 软海绵素b类似物
CN102803254B (zh) 2010-01-26 2016-09-14 卫材R&D管理有限公司 用于软海绵素b类似物合成的呋喃并[3,2-b]吡喃衍生物
WO2012147900A1 (fr) 2011-04-28 2012-11-01 Eisai R&D Management Co., Ltd. Procédé en microréacteurs pour synthèse d'analogue d'halichondrine b
CN105683198B (zh) 2013-11-04 2019-03-12 卫材R&D管理有限公司 软海绵素b的类似物合成中有用的大环化反应和中间体
HUE043088T2 (hu) 2013-12-06 2019-08-28 Eisai R&D Man Co Ltd Halikondrin B analógok szintézisében alkalmazható eljárások

Also Published As

Publication number Publication date
JP6001857B2 (ja) 2016-10-05
RU2010145171A (ru) 2012-05-20
US20140163244A1 (en) 2014-06-12
US9469651B2 (en) 2016-10-18
EP2274309A1 (fr) 2011-01-19
IL208410A0 (en) 2010-12-30
US8598373B2 (en) 2013-12-03
RU2517167C2 (ru) 2014-05-27
CN105801599A (zh) 2016-07-27
EP2274309B1 (fr) 2015-07-29
CA2720632C (fr) 2016-12-20
CN102056930B (zh) 2016-04-20
US20150315206A1 (en) 2015-11-05
CN102056930A (zh) 2011-05-11
US20110054194A1 (en) 2011-03-03
BRPI0911269A2 (pt) 2015-09-29
MX2010010902A (es) 2010-12-21
JP2011516493A (ja) 2011-05-26
JP2015063537A (ja) 2015-04-09
US9206194B2 (en) 2015-12-08
IL208410A (en) 2016-03-31
SG189739A1 (en) 2013-05-31
WO2009124237A1 (fr) 2009-10-08

Similar Documents

Publication Publication Date Title
CA2720632C (fr) Analogues b de l'halichondrine
US8148554B2 (en) Methods and compositions for use in treating cancer
WO2015081857A1 (fr) Maytansinoïdes anticancéreux présentant deux noyaux macrocycliques condensés
US8946246B2 (en) Synthetic rigidin analogues as anticancer agents, salts, solvates and prodrugs thereof, and method of producing same
RS50628B (sr) Derivati(poli)aminoacetamida epipodofilotoksina, postupak za njihovo dobijanje i njihove primene u terapeutici kao sredstva protiv kancera
CN105566338A (zh) 一种喜树碱类化合物及其制备方法和用途
WO2005062913A2 (fr) Derives de tritolide 5,6 en tant que immunomodulateurs et agents anticancereux
CN110343121B (zh) 双-(10-去氧双氢青蒿素)-间苯三酚缀合物的制备方法和应用
KR101496374B1 (ko) 항종양 활성을 갖는 캄프토테신 유도체
TW202114710A (zh) 作為sting促效劑之環狀二核苷酸
WO2012063250A1 (fr) Congénères de 4-bêta-acrylamidopodophyllotoxine substitués en tant qu'antibiotiques antitumoraux et leur procédé de préparation
AU2010210594B2 (en) Triptolide C-ring derivatives as anticancer agents and immune modulators
WO2013132263A1 (fr) Dérivés de picropodophylline pour utilisation en thérapie
CA2633543A1 (fr) Composes antitumoraux
KR20170105033A (ko) 항암제로서의 합성 리기딘 유사체, 이의 염, 용매화물 및 전구약물, 및 이를 제조하는 방법
CN101861309A (zh) Salarin和tulearin以及它们的组合物和应用
US20160207950A1 (en) Organometallic n-2-cyano-1-hydroxypropan-2-yl for use as anthelmintics
JPWO2012026433A1 (ja) 三環性ピラゾロピリミジン誘導体のフリー体結晶
WO2018167801A1 (fr) Nouveaux composés tricycliques, leur procédé de préparation et leur utilisation
WO2015044396A1 (fr) Dérivés de bis(composé organométallique) et de 2-amino-3-hydroxy-2-méthylpropanenitrile destinés à être utilisés comme anthelminthiques

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20140403

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 16TH ANNIV.) - STANDARD

Year of fee payment: 16

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250328

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250328